Vnitr Lek 2016, 62(9):699-702

Current position of a fixed combination telmisartan with amlodipine in treatment of essential arterial hypertension

Jiří Slíva
Ústav farmakologie 3. LF UK v Praze

Nowadays, fixed drug combinations are very important part of pharmacotherapy in essential arterial hypertension. The ameliorated activity of RAAS system (ACE inhibitors or sartans) along with calcium-ion channel inhibitor results in additive decrease of blood pressure with concomitant beneficial safety profile. Both telmisartan and amlodipine possess very favorable pharmacological properties, what is reflected in results of performed clinical trials, in which they were used as combinations.

Keywords: amlodipine; calcium channel blockers; fixed combination; hypertension; sartans; telmisartan

Received: July 10, 2016; Accepted: August 17, 2016; Published: September 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Current position of a fixed combination telmisartan with amlodipine in treatment of essential arterial hypertension. Vnitr Lek. 2016;62(9):699-702.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Corrao G, Zambon A, Parodi A et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26(4): 819-824. Go to original source... Go to PubMed...
    2. Mancia G, Fagard R, Narkiewicz K et al. [Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology]. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014; 23(1): 3-16. Go to original source... Go to PubMed...
    3. Burnier M, Vuignier Y, Wuerzner G. State-of-the-art treatment of hypertension: established and new drugs. Eur Heart J 2014; 35(9): 557-562. Go to original source... Go to PubMed...
    4. Verdecchia P, Gentile G, Angeli F et al. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis 2012; 6(2): 81-91. Go to original source... Go to PubMed...
    5. Tobe SW, Clase CM, Gao P et al. [ONTARGET and TRANSCEND Investigators]. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation 2011; 123(10): 1098-1107. Go to original source... Go to PubMed...
    6. Lacourciere Y, Lenis J, Orchard R et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3(5): 295-302. Go to PubMed...
    7. Kakuta H, Sudoh K, Sasamata M et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25(1): 41-46.
    8. Goyal SN, Bharti S, Bhatia J et al. Telmisartan, a dual ARB/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. Diabetes Obes.Metab 2011; 13(6): 533-541. Go to original source... Go to PubMed...
    9. Neldam S, Lang M, Jones R. [TEAMSTA-5 Investigators]. Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study. J Clin Hypertens (Greenwich) 2011; 13(7): 459-466. Go to original source... Go to PubMed...
    10. Neldam S, Edwards C, Jones R. [TEAMSTA-10 Investigators]. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin 2011; 27(11): 2145-2153. Go to original source... Go to PubMed...
    11. Neldam S, Edwards C, Lang M et al. [TEAMSTA-5 and TEAMSTA-10 Investigators]. Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. Curr Ther Res Clin Exp 2012; 73(1-2): 65-84. Go to original source... Go to PubMed...
    12. Neutel JM, Mancia G, Black HR et al. [TEAMSTA Severe HTN Study Investigators]. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich) 2012; 14(4): 206-215. Go to original source... Go to PubMed...
    13. Sharma AM, Bakris G, Neutel JM et al. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther 2012; 34(3): 537-551. Go to original source... Go to PubMed...
    14. Fogari R, Derosa G, Zoppi A et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 2007; 20(4): 417-422. Go to original source... Go to PubMed...
    15. Goyal J, Khan ZY, Upadhyaya P et. Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension. J Clin Diagn Res 2014; 8(6): HC08-HC11. Dostupné z DOI: <http://doi:10.7860/JCDR/2014/9352.4500>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.